

Molecular diagnosis of *PIK3CA*-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing

Paul Kuentz, MD¹⁻³, Judith St-Onge, DEC^{1,2,4}, Yannis Duffourd, MSc^{1,2}, Jean-Benoît Courcet, MD^{2,5}, Virginie Carmignac, PhD^{1,2}, Thibaud Jouan, BSc^{1,2}, Arthur Sorlin, MD^{1,2}, Claire Abasq-Thomas, MD⁶, Juliette Albuissou, MD, PhD⁷, Jeanne Amiel, MD, PhD⁸, Daniel Amram, MD⁹, Stéphanie Arpin, MD¹⁰, Tania Attie-Bitach, MD, PhD¹¹, Nadia Bahi-Buisson, MD, PhD⁸, Sébastien Barbarot, MD, PhD¹², Geneviève Baujat, MD⁸, Didier Bessis, MD¹³, Olivia Boccara, MD¹⁴, Maryse Bonnière, MD¹¹, Odile Boute, MD¹⁵, Anne-Claire Bursztejn, MD, PhD¹⁶, Christine Chiaverini, MD, PhD¹⁷, Valérie Cormier-Daire, MD, PhD⁸, Christine Coubes, MD¹⁸, Bruno Delobel, MD¹⁹, Patrick Edery, MD, PhD²⁰, Salima El Chehadeh, MD²¹, Christine Francannet, MD²², David Geneviève, MD, PhD¹⁸, Alice Goldenberg, MD²³, Damien Haye, MD²⁴, Bertrand Isidor, MD, PhD²⁵, Marie-Line Jacquemont, MD²⁶, Philippe Khau Van Kien, MD, PhD²⁷, Didier Lacombe, MD, PhD²⁸, Ludovic Martin, MD, PhD²⁹, Jelena Martinovic, MD³⁰, Annabel Maruani, MD, PhD³¹, Michèle Mathieu-Dramard, MD³², Juliette Mazereeuw-Hautier, MD, PhD³³, Caroline Michot, MD, PhD⁸, Cyril Mignot, MD, PhD³⁴, Juliette Miquel, MD³⁵, Fanny Morice-Picard, MD, PhD²⁸, Florence Petit, MD, PhD¹⁵, Alice Phan, MD, PhD³⁶, Massimiliano Rossi, MD, PhD²⁰, Renaud Touraine, MD, PhD³⁷, Alain Verloes, MD, PhD³⁸, Marie Vincent, MD²⁵, Catherine Vincent-Delorme, MD¹⁵, Sandra Whalen, MD³⁹, Marjolaine Willems, MD¹⁸, Nathalie Marle, MD^{1,2,40}, Daphné Lehalle, MD^{1,2,5}, Julien Thevenon, MD, PhD^{1,2,5}, Christel Thauvin-Robinet, MD, PhD^{1,2,5}, Smail Hadj-Rabia, MD, PhD¹⁴, Laurence Faivre, MD, PhD^{1,2,5}, Pierre Vabres, MD, PhD^{1,2,41} and Jean-Baptiste Rivière, PhD^{1,2,4,42}

Purpose: Postzygotic activating mutations of *PIK3CA* cause a wide range of mosaic disorders collectively referred to as *PIK3CA*-related overgrowth spectrum (PROS). We describe the diagnostic yield and characteristics of *PIK3CA* sequencing in PROS.

Methods: We performed ultradeep next-generation sequencing (NGS) of *PIK3CA* in various tissues from 162 patients referred to our clinical laboratory and assessed diagnostic yield by phenotype and tissue tested.

Results: We identified disease-causing mutations in 66.7% (108/162) of patients, with mutant allele levels as low as 1%. The diagnostic rate was higher (74%) in syndromic than in isolated cases (35.5%; $P = 9.03 \times 10^{-5}$). We identified 40 different mutations and found strong oncogenic mutations more frequently in patients without brain

overgrowth (50.6%) than in those with brain overgrowth (15.2%; $P = 0.00055$). Mutant allele levels were higher in skin and overgrown tissues than in blood and buccal samples ($P = 3.9 \times 10^{-25}$), regardless of the phenotype.

Conclusion: Our data demonstrate the value of ultradeep NGS for molecular diagnosis of PROS, highlight its substantial allelic heterogeneity, and confirm that optimal diagnosis requires fresh skin or surgical samples from affected regions. Our findings may be of value in guiding future recommendations for genetic testing in PROS and other mosaic conditions.

Genet Med advance online publication 2 February 2017

Key Words: molecular diagnosis; mosaicism; next-generation sequencing; *PIK3CA*; *PIK3CA*-related overgrowth spectrum

INTRODUCTION

Several developmental disorders are caused by mutations that occur early during embryogenesis (called “postzygotic” mutations) and result in a mosaic organism composed of genetically different cell populations despite their common origin.^{1,2} Although various mosaic syndromes have been recognized for

many years, most of their underlying genetic causes have been identified only recently, with the advent of next-generation sequencing (NGS). Following identification of a postzygotic gain-of-function mutation in *AKT1* as the cause of Proteus syndrome,³ several mosaic overgrowth conditions have been associated with postzygotic mutations in other members of the

Affiliation appears in last page.

Submitted 1 September 2016; accepted 23 November 2016; advance online publication 2 February 2017. doi:10.1038/gim.2016.220

PI3K-AKT-mTOR pathway.^{4–9} We and others reported postzygotic activating mutations of *PIK3CA* in a wide spectrum of developmental phenotypes previously recognized as distinct clinical entities, such as megalencephaly-capillary malformation (MCAP) syndrome,⁴ congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal (CLOVES) syndrome,⁷ and fibroadipose overgrowth (FAO).⁵ It was also proposed that at least some cases of Klippel-Trenaunay syndrome (KTS), a poorly defined umbrella term for disorders combining vascular malformation and mosaic limb overgrowth, may be caused by *PIK3CA* mutations.^{7,10,11} Key features of these distinct but overlapping *PIK3CA*-related disorders comprise congenital (or early childhood) and sporadic segmental overgrowth of varied body parts and tissues combined with vascular malformations, mosaic skin lesions such as epidermal nevi, and acral anomalies.^{12,13} In addition to these specific syndromes, postzygotic *PIK3CA* mutations were described in various isolated segmental or focal forms of overgrowth, including hemimegalencephaly (HMEG),⁶ megalencephaly (MEG),¹⁴ focal cortical dysplasia (FCD),^{15,16} hemihypertrophy, and macrodactyly.¹⁷ These genetic findings have significantly challenged the historical clinical classification of *PIK3CA*-related disorders. To avoid any further confusion in the field, the umbrella term of *PIK3CA*-related overgrowth spectrum (PROS) was proposed to designate known and emerging phenotypes caused by postzygotic *PIK3CA* mutations.¹³

PIK3CA encodes the p110 α catalytic subunit of the phosphatidylinositol 3-kinase and is the most commonly mutated proto-oncogene in human somatic cancer.¹⁸ Although dozens of activating *PIK3CA* mutations have been reported in tumors, three mutational hot spots with strong oncogenic activity (encoding p.Glu542Lys, p.Glu545Lys, and p.His1047Arg) account for ~80% of all somatic driver mutations in *PIK3CA*.^{18–20} Most identified mutations in patients with PROS have been reported in multiple unique somatic cancer samples,²¹ and the three aforementioned cancer hot-spot mutations have been found in a majority of patients with CLOVES, KTS, FAO, HMEG, and macrodactyly.^{5–7,12,17} A broader spectrum of rare (and possibly milder) *PIK3CA* mutations has been reported in patients with MCAP, along with some instances of de novo germ-line mutations.^{4,14}

Molecular diagnosis of PROS poses several challenges in terms of both biological samples and methodology. *PIK3CA* mutations can be found at greatly varying levels depending on the tissue tested and require sensitive methods for detecting low levels of mosaicism (<5%).^{4,13} Several research studies have described *PIK3CA* mutations in various disorders of PROS, and preliminary recommendations for clinical and molecular diagnosis have emerged from these fragmented results.¹³ However, our knowledge of the molecular basis of *PIK3CA*-related disorders remains limited, and no studies of NGS-based *PIK3CA* sequencing in clinical settings have been reported. Here, we describe our experience with 162 patients referred for *PIK3CA* testing at a clinical diagnostic laboratory, thus providing data regarding indications for testing, diagnostic yield,

tissues assayed, levels of mosaicism, and spectrum of pathogenic mutations.

MATERIALS AND METHODS

Study subjects

Our patient population consisted of 162 consecutive individuals with presumptive PROS referred to the molecular diagnostic laboratory of Dijon University Hospital for *PIK3CA* testing between October 2012 and June 2015. Referring physicians provided indication for testing as well as additional clinical information regarding brain and/or body overgrowth, vascular malformations, epidermal nevus, and acral anomalies (i.e., macrodactyly, syndactyly, polydactyly, and sandal-gap toes). Photographs of patients were also provided when available. Consistent with preliminary recommendations,¹³ minimum clinical criteria for testing included congenital, sporadic, and segmental overgrowth of adipose, muscle, skeletal, and/or cerebral tissue combined with at least one other key feature suggestive of PROS (“syndromic” category, **Table 1**). As previously proposed, individuals with isolated focal or segmental overgrowth were also considered to have presumptive PROS and were tested for *PIK3CA* mutations (“isolated” category; **Table 1**). Finally, we subdivided patients based on the presence or absence of brain overgrowth (i.e., megalencephaly or hemimegalencephaly (MEG/HMEG)). A list of all 162 affected individuals with clinical information, identified *PIK3CA* mutations, tissues tested, and mutant allele levels is provided in **Supplementary Table S1** online. We obtained written informed consent from all patients or their legal representatives, and the ethics committee of Dijon University Hospital approved the study.

Samples

PIK3CA testing for the diagnosis of PROS usually requires specimens from an affected region, such as a skin biopsy or a surgical sample from an overgrown tissue. Previous reports have shown that postzygotic *PIK3CA* mutations are generally not detectable in blood samples of affected individuals, except in patients with MCAP syndrome.^{4,13,14} We therefore strongly encouraged referring physicians to provide freshly obtained affected tissue samples such as skin biopsy specimens or surgical specimens from debulking procedures. Blood samples were accepted as primary samples for *PIK3CA* screening only for individuals with MEG/HMEG. We extracted genomic DNA from fresh skin, cultured skin fibroblasts, blood, saliva, cheek swabs, and surgical specimens from overgrown regions using the Gentra Puregene Blood and Tissue Extraction Kit (Qiagen, Courtaboeuf, France). We assessed genomic DNA integrity and quantity using agarose gel electrophoresis, NanoDrop spectrophotometry, and Qubit fluorometry (**Thermo Fischer Scientific, Courtaboeuf, France**).

Ultradeep sequencing of *PIK3CA*

We screened all *PIK3CA* coding exons (RefSeq accession number NM_006218.2) for mutations in one sample from

Table 1 Testing criteria and clinical categorization for *PIK3CA*-related overgrowth spectrum**Molecular diagnosis testing eligibility criteria:***Required:*

- Segmental/focal overgrowth (syndromic or isolated)
- Sporadic occurrence
- Congenital or early childhood onset

Recommended:

- Availability of fresh, uncultured affected tissue (skin or other tissues)

Clinical categorization—syndromic forms (at least two features, including overgrowth):

- Overgrowth (adipose, muscle, skeletal, cerebral)
- Vascular malformations (capillary, venous, lymphatic)
- Epidermal nevus
- Acral anomalies (macroductyly, syndactyly, polyductyly, sandal-gap toe)

Clinical categorization—isolated forms:

- Hemihypertrophy
- Hemifacial overgrowth
- Hemimegalencephaly or dysplastic megalencephaly
- Truncal adipose overgrowth
- Macroductyly or acral overgrowth (foot or hand)

Adapted from ref. 13.

each affected individual (referred to as the “primary sample tested”; **Supplementary Table S1** online). When available, fresh skin biopsy samples and surgical specimens were preferred over cultured skin fibroblast, buccal, and blood samples. We amplified regions of interest using custom intronic primers (**Supplementary Table S2** online) and long-range polymerase chain reactions with the PrimeSTAR GXL DNA Polymerase (Takara Bio, Saint-Germain-en-Laye, France). We pooled, purified, and quantified polymerase chain reaction amplicons from each affected individual. We prepared libraries using the Nextera XT DNA Sample Preparation kit (Illumina, Paris, France), which involves simultaneous fragmentation and tagging of DNA fragments by *in vitro* transposition.²² We performed paired-end sequencing reactions of 150-bp reads on a MiSeq platform using 300-cycle reagent kits (v2; Illumina, Paris, France).

Sequencing data analysis

We assessed the quality of sequencing reads with FastQC (v0.11.14)²³ and removed sequencing adapters and low-quality bases using Trimmomatic (v0.35).²⁴ We aligned reads to the human genome reference sequence GRCh37/hg19 with the Burrows-Wheeler Aligner (v0.7.12).²⁵ We performed realignment around insertions and deletions using the Genome Analysis Toolkit (GATK, v2.8-1).²⁶ Picard²⁷ and the GATK were used to collect quality-control, sequencing depth, and coverage metrics. As previously described,⁴ we identified candidate single-nucleotide variants and small insertions/deletions by recording all sites of *PIK3CA* coding exons and splice junctions with at least four reads not matching the reference

sequence and by using a stringent base quality threshold of 30 and a mapping quality threshold of 20. Variants were then hard-filtered to achieve minimum coverage at a site of 400 reads or more, with a mutant allele fraction of at least 0.01 (i.e., 10-fold higher than the average of 0.0010 errors per targeted base of our ultradeep sequencing assay). We annotated variants with SeattleSeq Annotation²⁸ and focused on protein-altering and splice-site changes present at a frequency less than 0.1% in the Exome Aggregation Consortium (ExAC).²⁹ Finally, we classified the remaining *PIK3CA* candidate variants according to the American College of Medical Genetics and Genomics guidelines.³⁰

Statistical analysis

Fisher's exact tests were used to test for significant differences in numbers of molecular diagnoses and numbers of *PIK3CA* mutations with strong oncogenic activity between phenotype groups. Mann-Whitney *U* tests were used to assess statistical differences in mutant allele fractions between tissue types.

RESULTS**Patients and samples**

The study comprised a total of 162 unrelated patients (82 females and 80 males), including 38 (23.5%) adults (defined as individuals 18 years of age and older), 118 (72.8%) minors, and 6 (3.7%) fetuses (**Supplementary Table S1** online). One hundred thirty-one (81%) were in the “syndromic” category and 31 (19%) were in the “isolated” category. Brain overgrowth (MEG/HMEG) was reported for 31% (50/162) of subjects, including 40 with a clinical diagnosis of MCAP syndrome (**Figure 1a**). Six patients, including four with brain overgrowth, were fetuses. Indications for testing, as provided by referring physicians, and patient counts are listed in **Supplementary Table S3** online. Of note, 14 patients (including one fetus) had an initial clinical diagnosis of Proteus syndrome. However, none met published diagnostic criteria for Proteus syndrome.³¹ Fresh skin biopsy specimens and surgical specimens comprised 82.7% (134/162) of all primary samples tested, and cultured skin fibroblasts accounted for 6.8% (11/162) of samples. Blood and buccal specimens were the primary samples tested for 17 affected individuals (**Figure 1b**). Consistent with testing eligibility criteria, all 11 blood samples screened for *PIK3CA* mutations were from individuals with MEG/HMEG, including eight with a clinical diagnosis of MCAP syndrome, two with isolated HMEG, and one with isolated MEG (**Supplementary Table S1** online).

Ultradeep sequencing of *PIK3CA*

NGS-based ultradeep sequencing of *PIK3CA* achieved a mean coverage of 6424.9-fold at coding bases and splice junctions, with 100 and 98.6% of bases covered by at least 100 and 1,000 reads, respectively. All candidate *PIK3CA* variants identified by our first screening were confirmed by a second, independent amplification reaction and sequencing experiment in the primary sample tested, confirming the high specificity of our assay.




Figure 1 Diagnostic rate of *PIK3CA* sequencing. (a) Total number of syndromic (dark gray) and isolated cases (light gray) by phenotype (with and without MEG/HMEG). (b) Primary tissues tested for all patients and by phenotype. (c) Molecular diagnostic rate as percentage of total cases in all patients and by phenotype. Numbers of cases with and without disease-causing *PIK3CA* mutations are shown in dark and light gray, respectively. * $P < 0.05$ for significant differences in diagnostic rates between syndromic and isolated cases. (d) Molecular diagnostic rate by primary tissue tested.

Molecular diagnostic yield

We identified and confirmed a pathogenic or likely pathogenic variant of *PIK3CA* in 66.7% (108/162) of patients (Figure 1c). The molecular diagnostic rate was similar between patients with (66%) and without brain overgrowth (67%). Overall, we found a significantly lower diagnostic rate in isolated cases than in syndromic cases (35.5 vs. 74%; two-tailed $P = 9.03 \times 10^{-5}$, Fisher exact test); this difference remained when considering only cases without brain overgrowth (33.3 vs. 74.7%; $P = 0.00057$). Although we observed the same tendency in the MEG/HMEG group (40 vs. 72.5%), the difference did not reach statistical significance ($P = 0.070$), probably due to the small sample size.

Clinical indications with the highest diagnostic yield comprised CLOVES syndrome (48/59, 81.4%), FAO (3/3, 100%), hemifacial overgrowth with or without HMEG (5/6, 83.3%), and MCAP syndrome (29/40, 72.5%) (Supplementary Table S3 online). Of interest, 78.6% (11/14) of cases with a clinical diagnosis of Proteus syndrome had a disease-causing *PIK3CA* mutation, further illustrating the high frequency of misdiagnosis of Proteus syndrome.³² We found disease-causing *PIK3CA* mutations in 46.2% (6/13) of patients with a clinical diagnosis of KTS, further supporting the idea that at least some patients with KTS should be included in the PROS.¹⁰ Indications with the lowest diagnostic yield were isolated focal or segmental forms of overgrowth with difficult access to overgrown specimens. These

included isolated hemihypertrophy or overgrown legs (2/12, 16.7%), macrodactyly (2/7, 28.6%), and HMEG (1/7, 14.3%). The only molecular diagnosis of isolated HMEG reported here was from a fetal brain sample. Brain tissues were not available for the remaining six HMEG patients (Supplementary Table S1 online).

Among the 54 patients with no *PIK3CA* mutation, subsequent molecular investigations identified the underlying genetic cause in two. A mosaic duplication of the 11p15.5 chromosomal region was found in a patient with an overgrown leg, and a postzygotic *GNAQ* mutation (NM_002072.3:c.548G>A, p.Arg183Gln) was identified in a patient with an initial clinical diagnosis of KTS, which was later revised to phakomatosis pigmentovascularis (Supplementary Table S1 online).³³

As anticipated, DNA derived from fresh skin and surgical specimens provided the highest diagnostic yield (92/134, 68.7%) (Figure 2d). The relatively high diagnostic rate in blood and buccal samples (10/17, 58.8%) is likely due to the bias in our testing eligibility criteria (see the Materials and Methods section for details).

Sample type and mosaicism

To investigate levels of mosaicism by tissue, we performed ultradeep sequencing of mutations of interest in all available samples from the 108 patients with identified *PIK3CA*

mutations. We screened a total of 201 specimens, most of which were fresh skin or overgrown tissues ($n = 99$) and blood samples ($n = 83$) (**Figure 2a**). The mutant allele fraction for each patient and tissue is provided in **Supplementary Figure S1** online. *PIK3CA* mutations were detected in all fresh skin and overgrown tissues tested, with a median mutant allele fraction of 0.14 (range, 0.01 to 0.47) (**Figure 2a**); 32.3 and 73.7% of these samples had a mutant allele fraction less than 0.1 and 0.2, respectively, thus highlighting the need for sensitive *PIK3CA* screening methods. Among the 13 cultured skin fibroblasts tested, the mutation was absent in three (23.1%), suggesting that cultured samples may not be ideal for *PIK3CA* mutation testing. As expected, we found that mutant allele levels were significantly higher in fresh skin and overgrown tissues than in blood and buccal samples when considering all patients (two-tailed $P = 3.9 \times 10^{-25}$, Mann-Whitney U test); this observation was also true for cases without ($P = 3.0 \times 10^{-24}$) and with MEG/HMEG ($P = 5.6 \times 10^{-5}$) (**Figure 2b**). Consistent with this observation, mutant allele levels were found to be systematically lower in blood and buccal samples than in fresh skin and overgrown tissues for any given patient, regardless of the phenotype (**Supplementary Figure S1** online). Mutant allele levels were significantly higher in blood and buccal samples of patients with than in those without MEG/HMEG ($P = 1.5 \times 10^{-7}$) (**Figure 2b**), further supporting previous observations that *PIK3CA* mutations are generally not detectable in blood or buccal samples of individuals with PROS, except in patients with MCAP syndrome.^{4,13,14} We found no such difference in mutant allele levels for skin and overgrown tissues between patients with and those without brain overgrowth ($P = 0.070$). We detected disease-causing *PIK3CA* mutations in 8.3% (5/60) of blood or buccal samples from individuals with no brain overgrowth. Mutant allele levels were generally low, with the highest peaking at 11.5% of total alleles. By comparison, *PIK3CA* mutations were detected in 58.6% (17/29) of blood or buccal samples from patients with MEG/HMEG, with mutant allele levels ranging from 1.4 to 50%. The only mutation present in 50% of alleles (NM_006218.2:c.3074C>A, p.Thr1025Asn)

was presumed to be germ-line and confirmed as *de novo* given its absence in parental blood samples. The patient (P1931) had isolated MEG with no signs of body overgrowth, vascular malformation, skin mosaicism, or acral anomalies.

Distribution and oncogenic activity of *PIK3CA* mutations

Overall, we identified 40 distinct nucleotide changes leading to 39 different amino acid changes in 108 patients (**Table 2**). All but one mutation were postzygotic. Twenty-two (55%) were seen in more than one patient (**Table 2** and **Figure 3a**). Although most mutations were missense changes, we identified two in-frame insertions/deletions encoding p.Gly106_Arg108delinsIle and p.Glu110del in four patients. Fifteen mutations (38.5%) had not been previously identified in patients with PROS, but most (37/40, 92.5%) were present in the Catalogue of Somatic Mutations in Cancer (COSMIC) at varying frequencies.²¹ Three (encoding p.Glu545Lys, p.His1047Arg, and p.His1047Leu) were present in ExAC,²⁹ with each being reported in only one of ~120,000 alleles (**Table 2**). It is unknown whether these ExAC variants are true (yet extremely rare) variants in the general population, false positives, or somatic mutations from cancer samples or patients. Of note, the only *AKT1* mutation known to cause Proteus syndrome (NM_005163.2:c.49G>A, p.Glu17Lys)³ is also reported in one ExAC allele, despite being thought to be incompatible with life in a germ-line state.

Among the 39 amino acid changes identified in the present study, 17 were found only in patients without MEG/HMEG, 9 were found in patients with MEG/HMEG, and 13 were shared by both groups (**Figure 3a**). To explore genotype-phenotype correlations based on the mutation effect, we used results from a recent study that aimed to characterize the oncogenic potential of somatic *PIK3CA* mutations found in cancer. The authors performed *in vitro* and *in vivo* cell growth and oncogenic transformation experiments to characterize the functional impact of 27 *PIK3CA* mutations.³⁴ Oncogenic activity, classified from weak to strong, was available for 13 of the *PIK3CA* mutations identified in the present study, including the three strong oncogenic hot spots p.Glu542Lys, p.Glu545Lys, and p.His1047Arg




Figure 2 Levels of *PIK3CA* mutations by sample type. (a) Swarm plot showing mutant allele fractions in samples from patients with (light gray) and without (dark gray) MEG/HMEG. Tested samples included skin and overgrown tissues ($n = 99$), cultured skin fibroblasts ($n = 13$), saliva and buccal swabs ($n = 6$), and blood ($n = 83$). (b) Box and whisker plots showing mutant allele fractions in affected (skin and overgrown tissues) and surrogate samples (buccal and blood samples).

Table 2 Summary of *PIK3CA* mutations identified in 108 cases

gDNA change	cDNA change ^a	Amino acid change	COSMIC ^b	ExAC ^c	Oncogenic activity ^d	No MEG/ HMEG	MEG/ HMEG	Previously reported in PROS
chr3:g.178916854G>A	c.241G>A	p.Glu81Lys	45	0	Unknown	1	1	Yes
chr3:g.178916924C>T	c.311C>T	p.Pro104Leu	7	0	Unknown	2	1	Yes
chr3:g.178916929_178916936 delinsAT	c.316_323delinsAT	p.Gly106_ Arg108delinsIle	0 ^e	0	Unknown	1	0	No
chr3:g.178916930G>T	c.317G>T	p.Gly106Val	17	0	Unknown	1	0	Yes
chr3:g.178916941_178916943del	c.328_330del	p.Glu110del	1	0	Unknown	1	2	No
chr3:g.178916957G>C	c.344G>C	p.Arg115Pro	1	0	Unknown	1	0	Yes
chr3:g.178917478G>A	c.353G>A	p.Gly118Asp	39	0	Unknown	2	1	Yes
chr3:g.178921553T>A	c.1035T>A	p.Asn345Lys	82	0	Strong	1	0	No
chr3:g.178922321G>A	c.1090G>A	p.Gly364Arg	3	0	Unknown	1	0	Yes
chr3:g.178922324G>A	c.1093G>A	p.Glu365Lys	11	0	Unknown	2	0	Yes
chr3:g.178922364G>A	c.1133G>A	p.Cys378Tyr	2	0	Unknown	1	3	Yes
chr3:g.178927974G>A	c.1252G>A	p.Glu418Lys	12	0	Unknown	0	2	No
chr3:g.178927980T>C	c.1258T>C	p.Cys420Arg	73	0	Strong	3	0	Yes
chr3:g.178928067C>A	c.1345C>A	p.Pro449Thr	4	0	Unknown	0	1	Yes
chr3:g.178928079G>A	c.1357G>A	p.Glu453Lys	25	0	Intermediate	8	2	Yes
chr3:g.178928226C>T	c.1412C>T	p.Pro471Leu	10	0	Unknown	0	1	No
chr3:g.178936082G>A	c.1624G>A	p.Glu542Lys	908	0	Strong (hot spot)	5	1	Yes
chr3:g.178936083A>G	c.1625A>G	p.Glu542Gly	6	0	Unknown	0	1	No
chr3:g.178936091G>A	c.1633G>A	p.Glu545Lys	1444	1	Strong (hot spot)	7	1	Yes
chr3:g.178936094C>A	c.1636C>A	p.Gln546Lys	158	0	Strong	1	0	Yes
chr3:g.178936095A>G	c.1637A>G	p.Gln546Arg	56	0	Strong	2	0	No
chr3:g.178936096G>C	c.1638G>C	p.Gln546His	0 ^f	0	Unknown	1	0	Yes
chr3:g.178938934G>A	c.2176G>A	p.Glu726Lys	36	0	Unknown	4	2	Yes
chr3:g.178947827G>T	c.2702G>T	p.Cys901Phe	10	0	Unknown	1	0	No
chr3:g.178947852C>A	c.2727C>A	p.Phe909Leu	1	0	Unknown	1	1	No
chr3:g.178947865G>A	c.2740G>A	p.Gly914Arg	1	0	Unknown	3	0	Yes
chr3:g.178947866G>C	c.2741G>C	p.Gly914Ala	0	0	Unknown	1	0	No
chr3:g.178952006T>C	c.3061T>C	p.Tyr1021His	4	0	Unknown	1	0	Yes
chr3:g.178952007A>G	c.3062A>G	p.Tyr1021Cys	40	0	Unknown	0	1	Yes
chr3:g.178952019C>A	c.3074C>A	p.Thr1025Asn	4	0	Unknown	0	1	No
chr3:g.178952049C>T	c.3104C>T	p.Ala1035Val	4	0	Unknown	1	1	Yes
chr3:g.178952072A>G	c.3127A>G	p.Met1043Val	31	0	Strong	2	0	No
chr3:g.178952074G>A	c.3129G>A	p.Met1043Ile	28	0	Intermediate	0	2	Yes
chr3:g.178952074G>T	c.3129G>T	p.Met1043Ile	69	0	Intermediate	0	1	Yes
chr3:g.178952077T>G	c.3132T>G	p.Asn1044Lys	6	0	Weak	1	0	No
chr3:g.178952084C>T	c.3139C>T	p.His1047Tyr	72	0	Intermediate	2	1	Yes
chr3:g.178952085A>G	c.3140A>G	p.His1047Arg	1951	1	Strong (hot spot)	13	3	Yes
chr3:g.178952085A>T	c.3140A>T	p.His1047Leu	285	1	Strong	4	0	Yes
chr3:g.178952086T>A	c.3141T>A	p.His1047Gln	3	0	Unknown	0	1	No
chr3:g.178952093G>A	c.3148G>A	p.Gly1050Ser	1	0	Unknown	0	2	No

cDNA, complementary DNA; COSMIC, Catalogue of Somatic Mutations in Cancer; ExAC, Exome Aggregation Consortium; gDNA, genomic DNA; MEG/HMEG, megalencephaly/hemimegalencephaly; PROS, *PIK3CA*-related overgrowth spectrum.

^aThe RefSeq accession number used for variant nomenclature is NM_006218.2. ^bNumber of cancer samples with the identified *PIK3CA* mutation in COSMIC (<http://cancer.sanger.ac.uk/>; accessed August 2016). ^cNumber of alleles reported by ExAC (<http://exac.broadinstitute.org/>; accessed August 2016). ^dAccording to Dogruluk et al.³⁴ ^ep.Gly106_Arg108del was reported in 3 samples in COSMIC. ^fA different nucleotide change (c.1638G>T) leading to the same amino acid change (p.Gln546His) was reported in 10 samples in COSMIC.

(Table 2). Consistent with previous findings,^{4,14,35} we found strong oncogenic mutations more frequently in patients without (50.6%) than in those with brain overgrowth (15.2%; two-tailed

$P = 0.00055$, Fisher exact test) (Figure 3b). Nevertheless, only 33.3% of our patients without brain overgrowth had one of the three *PIK3CA* hot-spot mutations, which is in striking




Figure 3 Distribution and oncogenic activity of *PIK3CA* mutations. (a) Distribution of the mutations identified in cases without (dark gray) and with MEG/HMEG (light gray). (b) Oncogenic activity of the identified *PIK3CA* mutations in cases without (left pane) and with MEG/HMEG (right pane). Oncogenic activity, from weak to strong effect, is illustrated by a gray scale. Mutations with unknown effects are shown in light gray.

contrast with previous reports that such mutations were the cause of CLOVES, KTS, FAO, and other focal forms of body overgrowth in a majority of patients.^{12,14} Interestingly, among the five patients with MEG/HMEG caused by one of the three cancer hot-spot mutations, two were fetuses with severe brain overgrowth, two had severe hemifacial overgrowth and HMEG, and only one had a postnatal clinical diagnosis of MCAP syndrome, further supporting the idea that MCAP is rarely caused by strong oncogenic *PIK3CA* hot-spot mutations.¹⁴

DISCUSSION

To our knowledge, this is the first report of the use of NGS for molecular diagnosis of disorders of the PROS in a clinical setting. Ultradeep sequencing of *PIK3CA* had a diagnostic rate of 66.7% in our series, with a significantly better yield for syndromic than for isolated forms. We showed that freshly obtained skin biopsy specimens and other surgical specimens from affected regions are the most suitable samples for optimal molecular diagnosis of PROS, regardless of the phenotype. Our findings also highlight the substantial allelic heterogeneity of PROS, illustrate the absence of strong genotype–phenotype correlations between clinical subgroups, underline the limitations of the historical sub-classification of these disorders into

distinct syndromes, and confirm the relevance and utility of the preliminary recommendations for clinical assessment and molecular diagnosis of PROS.¹³

Identifying postzygotic mutations commonly present at levels below the detection threshold of capillary-based Sanger sequencing poses significant challenges to conventional molecular diagnosis. We showed that extremely deep (>1,000-fold) NGS-based sequencing of *PIK3CA* can readily detect levels of mutations as low as 1%. In addition to detecting single-nucleotide changes, our approach was able to identify postzygotic insertions and deletions, including a complex indel present in 7.8% of alleles and characterized by a deletion of eight and an insertion of two nucleotides. The substantial number of different disease-causing mutations (40 identified in this study alone, including 15 previously unreported) entails sequencing all coding exons of *PIK3CA*. Given the well-known limitations of Sanger sequencing for detecting mosaic variants,⁴ NGS-based ultradeep sequencing of *PIK3CA* appears to be the best available method for molecular diagnosis of PROS.

We observed a significantly higher number of molecular diagnoses in syndromic than in isolated forms of presumptive PROS. One reason could be that collecting affected specimens from patients with isolated anomalies may prove challenging,

especially if no debulking or epilepsy surgery is planned. Our findings indicate that skin biopsy specimens from nonlesional regions and other surrogate samples are of little help for molecular diagnosis of isolated forms of PROS and emphasize the need for affected samples. Another reason could be that some of these phenotypes may be less specific than syndromic forms and due to other genetic causes, such as mutations in other members of the PI3K-AKT-mTOR pathway or mosaic forms of autosomal-dominant overgrowth syndromes, as illustrated by our patient with a mosaic duplication of the 11p15.5 region, which is a rare cause of Beckwith-Wiedemann syndrome.³⁶

Considerations regarding which tissues to test are crucial for the optimal molecular diagnosis of mosaic disorders. Our data show that freshly obtained skin biopsy specimens and other surgical specimens from affected regions provide the best results in terms of diagnostic yield and mutant allele levels. Standard procedures of clinical laboratories for skin biopsies often involve isolating and culturing skin fibroblasts. Although based on a limited number of samples, our data suggest that fresh skin samples should be preferred over cultured cells for *PIK3CA* mutation screening. In addition to missing mutations that might have been detected in the original skin biopsy, cultured cells are prone to genetic alterations and drift. This may lead to false-positive results (i.e., cell culture artifacts), especially with methods meant to detect very low mutant allele levels.³⁷

We confirmed previous observations that *PIK3CA* mutations are detectable in blood or buccal samples of a significant fraction of patients with MCAP syndrome.^{4,14} Nonetheless, our data show that blood and buccal samples lead to lower diagnostic rates and mutant allele levels than skin and other affected tissues. We therefore recommend a uniform approach based on affected skin and overgrown tissues as primary samples for molecular diagnosis of all disorders of PROS.

It has been proposed that disorders of PROS with no brain overgrowth such as CLOVES, FAO, or KTS are mostly caused by *PIK3CA* cancer hot-spot mutations, whereas MCAP is usually associated with rarer and milder gain-of-function mutations.¹⁴ Although we found a higher number of cancer hot-spot mutations in patients without brain overgrowth, the majority were caused by rare *PIK3CA* mutations, thus demonstrating that both MCAP and non-MCAP phenotypes have a broad mutational spectrum. We also found various mutations in more than one distinct clinical entity, further strengthening the idea that *PIK3CA*-associated phenotypes should be considered as a single spectrum. Our data confirm the advantage of using the umbrella term of PROS over historical clinical classifications for assessment of overgrowth and molecular diagnostic testing.¹³

In conclusion, our findings may help to define future best practices for molecular diagnosis of PROS in particular and mosaic developmental disorders in general. Along with the emergence of specific inhibitors of the PI3K-AKT-mTOR pathway,³⁸ accurate molecular diagnoses of PROS will be crucial for paving the way toward effective treatments for patients with these disorders.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at <http://www.nature.com/gim>

ACKNOWLEDGMENTS

We thank the subjects and families involved in the study, their referring physicians, and M-CM France (<http://m-cmfrance.com/>). We also thank the University of Burgundy Centre de Calcul (CCuB) for technical support and management of the informatics platform. This work was funded by the Agence Nationale de la Recherche (ANR-13-PDOC-0029 to J.-B.R.), the Groupe Inter-régional de Recherche Clinique et d'Innovation (GIRCI) Est (to J.-B.R.), the Programme Hospitalier de Recherche Clinique (PHRC) National, and the Société Française de Dermatologie (to P.V.).

DISCLOSURE

The authors declare no conflict of interest.

The last three authors jointly supervised this work.

The first three authors contributed equally to this work.

¹Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France; ²Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université Bourgogne Franche-Comté, Dijon, France; ³Génétique Biologique Histologie, CHRU de Besançon, Besançon, France; ⁴Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; ⁵Service de Pédiatrie 1 et de Génétique Médicale, CHU Dijon Bourgogne, Dijon, France; ⁶Département de Pédiatrie et Génétique Médicale, CHU Brest Morvan, Brest, France; ⁷Centre de Référence des Maladies Vasculaires Rares, Hôpital Européen Georges Pompidou, Paris, France; ⁸Service de Génétique Médicale, Hôpital Necker-Enfants Malades, Paris, France; ⁹Unité de Génétique Clinique, CHI de Créteil, Créteil, France; ¹⁰Service de Génétique Clinique, CHRU de Tours, Tours, France; ¹¹Service d'Histologie-Embryologie-Cytogénétique, Hôpital Necker-Enfants Malades, Paris, France; ¹²Service de Dermatologie, CHU de Nantes, Nantes, France; ¹³Département de Dermatologie, CHRU de Montpellier, Montpellier, France; ¹⁴Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris Descartes—Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, Paris, France; ¹⁵Service de Génétique Clinique, CHU Lille, Lille, France; ¹⁶Service de Dermatologie, CHU de Nancy, Nancy, France; ¹⁷Service de Dermatologie, CHU de Nice, Nice, France; ¹⁸Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France; ¹⁹Centre de Génétique Chromosomique, GH de l'Institut Catholique de Lille, Lille, France; ²⁰Genetics Department, Hospices Civils de Lyon and GENDEV team, Lyon Neuroscience Research Centre, INSERM U1028, CNRS UMR 5292, Claude Bernard Lyon 1 University, Lyon, France; ²¹Service de Génétique Médicale, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; ²²Service de Génétique Médicale, CHU de Clermont-Ferrand, Clermont-Ferrand, France; ²³Service de Génétique, CHU de Rouen et Inserm U1079, Université de Rouen, Centre Normand de Génétique Médicale et Médecine Personnalisée, Rouen, France; ²⁴Service de Pédiatrie, CHU de Tours, Tours, France; ²⁵Service de Génétique Médicale, CHU de Nantes, Nantes, France; ²⁶Unité de Génétique Médicale, CHU de la Réunion, Saint-Pierre, France; ²⁷Unité de Génétique Médicale et Cytogénétique, CHU de Nîmes, Nîmes, France; ²⁸INSERM U1211, Université de Bordeaux, Service de Génétique Médicale, CHU de Bordeaux, Bordeaux, France; ²⁹Service de Dermatologie, CHU d'Angers, Angers, France; ³⁰Unité de Fœtopathologie, APHP, Hôpital Antoine-Béclère, Clamart, France; ³¹Université François-Rabelais, Service de Dermatologie, Unité de Dermatologie Pédiatrique, CIC Inserm 1415, Tours, France; ³²Centre d'Activité de Génétique Clinique et Oncogénétique, CHU d'Amiens, Amiens, France; ³³Centre de Référence des Maladies Rares de la Peau, CHU de Toulouse, Toulouse, France; ³⁴APHP, Département de Génétique et Cytogénétique, Centre de Référence Déficiences Intellectuelles de Causes Rares, GRC UPMC Déficiences Intellectuelles et Autisme, GH La Pitié Salpêtrière, Paris, France; ³⁵Service de Pédiatrie Générale, CHU de la Réunion, Saint-Pierre, France; ³⁶Service de Dermatologie, CHU de Lyon, Lyon, France; ³⁷Service de Génétique Clinique, CHU de Saint-Etienne, Saint-Priest-en-Jarez, France; ³⁸Unité Fonctionnelle de Génétique Clinique, Hôpital Robert Debré, Paris, France; ³⁹Unité Fonctionnelle de Génétique Clinique, Hôpital Armand-Trousseau, Paris, France; ⁴⁰Laboratoire de Génétique Chromosomique et Moléculaire, CHU Dijon Bourgogne, Dijon, France; ⁴¹Service de Dermatologie, CHU Dijon Bourgogne, Dijon, France; ⁴²Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. Correspondence: Jean-Baptiste Rivière (jean-baptiste.riviere@mcgill.ca)

REFERENCES

1. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. *Nat Rev Genet* 2013;14:307–320.
2. Happle R. *Mosaicism in Human Skin: Understanding Nevus, Nevroid Skin Disorders, and Cutaneous Neoplasia*. Springer: Heidelberg, Germany, 2014.
3. Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. *N Engl J Med* 2011;365:611–619.
4. Rivière JB, Mirzaa GM, O'Roak BJ, et al.; Finding of Rare Disease Genes (FORGE) Canada Consortium. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. *Nat Genet* 2012;44:934–940.
5. Lindhurst MJ, Parker VE, Payne F, et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. *Nat Genet* 2012;44:928–933.
6. Lee JH, Huynh M, Silhavy JL, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. *Nat Genet* 2012;44:941–945.
7. Kurek KC, Luks VL, Ayturk UM, et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. *Am J Hum Genet* 2012;90:1108–1115.
8. Hussain K, Challis B, Rocha N, et al. An activating mutation of AKT2 and human hypoglycemia. *Science* 2011;334:474.
9. Lim JS, Kim WI, Kang HC, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. *Nat Med* 2015;21:395–400.
10. Vahidnezhad H, Youssefian L, Uitto J. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). *Exp Dermatol* 2016;25:17–19.
11. Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. *J Pediatr* 2015;166:1048–54.e1.
12. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. *Am J Med Genet A* 2014;164A:1713–1733.
13. Keppler-Noreuil KM, Rios JJ, Parker VE, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. *Am J Med Genet A* 2015;167A:287–295.
14. Mirzaa G, Timms AE, Conti V, et al. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. *JCI Insight* 2016;1:e87623.
15. D'Gama AM, Geng Y, Couto JA, et al. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. *Ann Neurol* 2015;77:720–725.
16. Jansen LA, Mirzaa GM, Ishak GE, et al. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. *Brain* 2015;138(Pt 6):1613–1628.
17. Rios JJ, Paria N, Burns DK, et al. Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. *Hum Mol Genet* 2013;22:444–451.
18. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. *Nature* 2013;502:333–339.
19. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490:61–70.
20. Hoadley KA, Yau C, Wolf DM, et al.; Cancer Genome Atlas Research Network. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell* 2014;158:929–944.
21. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Res* 2015;43(Database issue):D805–D811.
22. Caruccio N. Preparation of next-generation sequencing libraries using Nextera™ technology: simultaneous DNA fragmentation and adaptor tagging by in vitro transposition. *Methods Mol Biol* 2011;733:241–255.
23. Babraham Bioinformatics. FastQC. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.
24. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;30:2114–2120.
25. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 2010;26:589–595.
26. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297–1303.
27. Broad Institute. Picard. <https://broadinstitute.github.io/picard/>.
28. SeattleSeq. SeattleSeq Annotation 138. <http://snp.gs.washington.edu/SeattleSeqAnnotation138/>.
29. Lek M, Karczewski KJ, Minikel EV, et al.; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285–291.
30. Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405–424.
31. Biesecker LG, Happle R, Mulliken JB, et al. Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. *Am J Med Genet* 1999;84:389–395.
32. Cohen MM Jr, Turner JT, Biesecker LG. Proteus syndrome: misdiagnosis with PTEN mutations. *Am J Med Genet A* 2003;122A:323–324.
33. Thomas AC, Zeng Z, Rivière JB, et al. Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. *J Invest Dermatol* 2016;136:770–778.
34. Dogruluk T, Tsang YH, Espitia M, et al. Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. *Cancer Res* 2015;75:5341–5354.
35. Mirzaa GM, Rivière JB, Dobyns WB. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP. *Am J Med Genet C Semin Med Genet* 2013;163C:122–130.
36. Shuman C, Beckwith JB, Weksberg R. Beckwith-Wiedemann syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). *GeneReviews*. University of Washington: Seattle, WA, 1993.
37. Carlson CA, Kas A, Kirkwood R, et al. Decoding cell lineage from acquired mutations using arbitrary deep sequencing. *Nat Methods* 2011;9:78–80.
38. Parker VE, Knox RG, Zhang Q, Wakelam MJ, Semple RK. Phosphoinositide 3-kinase-related overgrowth: cellular phenotype and future therapeutic options. *Lancet* 2015;385(suppl 1):S77.